Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration

Swikriti Dasgupta, Michio Imamura, Evan Gorstein, Takashi Nakahara, Masataka Tsuge, Alexander Churkin, David Yardeni, Ohad Etzion, Susan L. Uprichard, Danny Barash, Scott J. Cotler, Harel Dahari, Kazuaki Chayama

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising efficacy, confirming our retrospective modeling reports in >200 patients. However, retrospective modeling of pibrentasvir-glecaprevir (P/G) treatment has yet to be evaluated. In the current study, modeling hepatitis C virus kinetics in 44 cirrhotic and noncirrhotic patients predicts that P/G treatment might have been reduced to 4, 6, and 7 weeks in 16%, 34%, and 14% of patients, respectively. These results support the further evaluation of a modeling-based response-guided therapy approach using P/G.

Original languageEnglish
Pages (from-to)1165-1169
Number of pages5
JournalJournal of Infectious Diseases
Volume222
Issue number7
DOIs
StatePublished - 1 Oct 2020

Keywords

  • Direct-acting antivirals
  • Hepatitis C virus
  • Mathematical modeling
  • Response-guided therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Modeling-Based response-guided glecaprevir-pibrentasvir therapy for chronic hepatitis C to identify patients for ultrashort treatment duration'. Together they form a unique fingerprint.

Cite this